Across TCGA pan-cancer cohorts, CCSAP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCSAP data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher CCSAP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCSAP expression acts as an unfavorable survival marker.
COAD, SCLC, and PRAD are the cancer types where CCSAP Mutation most reproducibly stratifies survival.